Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 3 Recruiting Industry
This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of sk…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06246916
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 3 Recruiting Industry
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Sponsor: Aura Biosciences
NCT ID: NCT06007690
Sites in Wisconsin: - University of Wisconsin Madison — Madison, Wisconsin
Phase 3 Recruiting Industry
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Sponsor: IDEAYA Biosciences
NCT ID: NCT07015190
Sites in Wisconsin: - University of Wisconsin Health — Madison, Wisconsin
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with im…
Sponsor: Replimune, Inc.
NCT ID: NCT06581406
Sites in Wisconsin: - University Of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 2 Recruiting Network
This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binime…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT04511013
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
Phase 2 Recruiting NIH
This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
Phase 2 Recruiting NIH
This phase II trial tests whether nivolumab in combination with cabozantinib works in patients with mucosal melanoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05111574
Sites in Wisconsin: - HSHS Sacred Heart Hospital — Eau Claire, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
Phase 2 Recruiting Industry
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL \[LN-144/LN-145 (lifileucel)\] in combination with immune checkpoint inhibitors or TIL \[LN-144/LN-145 (lifi…
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT03645928
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent administered intravenously in participants with advanced solid tumors that are antigen-ri…
Sponsor: Marengo Therapeutics, Inc.
NCT ID: NCT05592626
Sites in Wisconsin: - University of Wisconsin- Madison — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, efficacy, optimal dose, and pharmacokinetics (PK) of BNT326 as monotherapy (Part 1) and as combination treatment with immunotherapeutic agents (Part 2) in participants with histologically or cytological…
Sponsor: BioNTech SE
NCT ID: NCT07070232
Sites in Wisconsin: - The Board of Regents of the University of Wisconsin — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
In this first-in human, phase I/IIa study, the safety and efficacy of \[212Pb\]VMT01, an alpha-particle emitting therapeutic agent targeted to melanocortin sub-type 1 receptor (MC1R) is being evaluated as a monotherapy and in combination w…
Sponsor: Perspective Therapeutics
NCT ID: NCT05655312
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05361174
Sites in Wisconsin: - Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety, tolerability, and preliminary effectiveness of AMXT 1501 and DFMO when combined with standard treatments for advanced solid tumors. The trial includes two groups: * Cohort 1: Patients with ER+ / HER2- b…
Sponsor: Aminex Therapeutics, Inc.
NCT ID: NCT07287917
Sites in Wisconsin: - University of Wisconsin-Madison Carbone Cancer Center — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Academic/Other
This study is being done to see if combining HEPZATO KIT™ with nivolumab and relatlimab (Opdualag™) in the first line setting in patients with metastatic melanoma with liver metastasis is safe, tolerable, and will have a synergistic effect…
Sponsor: University of Wisconsin, Madison
NCT ID: NCT07281924
Sites in Wisconsin: - UW Hospital and Clinics — Madison, Wisconsin
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…
Sponsor: Pfizer
NCT ID: NCT05538130
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 1 Recruiting Industry
Patients with Small Cell Lung Cancer, High Risk Neuroblastoma, Sarcoma and Malignant Melanoma will be treated with GD2-SADA:177Lu-DOTA complex(The IMP is a two-step radioimmunotherapy, delivered as two separate products GD2-SADA and 177Lu-…
Sponsor: Y-mAbs Therapeutics
NCT ID: NCT05130255
Sites in Wisconsin: - University of Wisconsin-Madison — Madison, Wisconsin
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Wisconsin: - Aspirus Langlade Hospital — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Ascension Saint Elizabeth Hospital — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- ThedaCare Cancer Care - Berlin — Berlin, Wisconsin
NA Recruiting Network
The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
Sponsor: Eastern Cooperative Oncology Group
NCT ID: NCT05108298
Sites in Wisconsin: - Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
- Gundersen Lutheran Medical Center — La Crosse, Wisconsin
- Cancer Center of Western Wisconsin — New Richmond, Wisconsin
- Saint Vincent Hospital Cancer Center at Oconto Falls — Oconto Falls, Wisconsin
Recruiting Network
This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going ca…
Sponsor: Children's Oncology Group
NCT ID: NCT02402244
Sites in Wisconsin: - Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
- Marshfield Medical Center-Marshfield — Marshfield, Wisconsin
- Children's Hospital of Wisconsin — Milwaukee, Wisconsin
NA Recruiting Academic/Other
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1…
Sponsor: Melanoma and Skin Cancer Trials Limited
NCT ID: NCT03860883
Sites in Wisconsin: - University of Winsconsin Carbone Cancer Center-Eastpark medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center — Madison, Wisconsin
- Marshfield Medical Center - Marshfield — Marshfield, Wisconsin
- Aurora St Luke's Medical Center — Milwaukee, Wisconsin
- Medical College of Wisconsin — Milwaukee, Wisconsin
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Wisconsin: - Massive Bio SYNERGY-AI site — Milwaukee, Wisconsin
Recruiting Academic/Other
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, h…
Sponsor: University of Nebraska
NCT ID: NCT02012699
Sites in Wisconsin: - Bellin Memorial Hospital — Green Bay, Wisconsin
Recruiting Industry
The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinica…
Sponsor: Guardant Health, Inc.
NCT ID: NCT05059444
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin